Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) FCF Margin (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed FCF Margin for 5 consecutive years, with 26.84% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin rose 27103.0% year-over-year to 26.84%; the TTM value through Mar 2026 reached 47.69%, up 29782.0%, while the annual FY2025 figure was 95.37%, 38770.0% up from the prior year.
  • FCF Margin hit 26.84% in Q1 2026 for Phathom Pharmaceuticals, down from 8.99% in the prior quarter.
  • Across five years, FCF Margin topped out at 1626.57% in Q1 2022 and bottomed at 6254.55% in Q4 2023.
  • Average FCF Margin over 5 years is 647.86%, with a median of 93.71% recorded in 2025.
  • Year-over-year, FCF Margin crashed -667685bps in 2023 and then soared 604061bps in 2024.
  • Phathom Pharmaceuticals' FCF Margin stood at 422.31% in 2022, then plummeted by -1581bps to 6254.55% in 2023, then skyrocketed by 97bps to 213.93% in 2024, then surged by 96bps to 8.99% in 2025, then crashed by -198bps to 26.84% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 26.84%, 8.99%, and 28.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.